Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

BACKGROUND: Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-2 therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735508/
https://www.ncbi.nlm.nih.gov/pubmed/29254506
http://dx.doi.org/10.1186/s40425-017-0307-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735508/
https://www.ncbi.nlm.nih.gov/pubmed/29254506
http://dx.doi.org/10.1186/s40425-017-0307-5

Ejemplares similares